Clovis Oncology

+$0.0158 (+2.34%) Today
+$0.0099 (+1.43%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CLVS and other ETFs, options, and stocks.

About CLVS

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.

CEO
Patrick J. Mahaffy
Employees
413
Headquarters
Boulder, Colorado
Founded
2009

CLVS Key Statistics

Market cap
99.90M
Price-Earnings ratio
—
Dividend yield
—
Average volume
3.87M
High today
$0.72
Low today
$0.62
Open price
$0.72
Volume
4.55M
52 Week high
$7.24
52 Week low
$0.6105

CLVS Earnings

-$0.99
-$0.66
-$0.33
$0.00
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 3, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure